The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-[4-(4-Fluorophenyl)-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl]phenol ID: ALA2179119
PubChem CID: 136236302
Max Phase: Preclinical
Molecular Formula: C28H19FN4O
Molecular Weight: 446.49
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)cc1
Standard InChI: InChI=1S/C28H19FN4O/c29-20-10-6-18(7-11-20)25-26(33-27(32-25)19-8-12-21(34)13-9-19)22-14-15-30-28-23(22)16-24(31-28)17-4-2-1-3-5-17/h1-16,34H,(H,30,31)(H,32,33)
Standard InChI Key: HFDJAPMETZJFMI-UHFFFAOYSA-N
Molfile:
RDKit 2D
34 39 0 0 0 0 0 0 0 0999 V2000
4.6341 -10.0070 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.4139 -9.7626 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.4243 -8.9453 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6475 -8.6836 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.1631 -9.3406 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1163 -8.5168 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8354 -8.9073 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5310 -8.4798 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5087 -7.6621 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7849 -7.2736 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0923 -7.7033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3488 -9.3343 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9479 -8.6209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1315 -8.6124 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7151 -9.3166 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1209 -10.0307 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9360 -10.0357 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1204 -10.1680 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5363 -10.9832 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.5320 -10.1618 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8237 -9.7585 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8284 -11.3933 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1202 -10.9844 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5124 -11.5315 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.8450 -12.2787 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6583 -12.1932 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.2042 -7.2330 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
5.4385 -12.9842 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6202 -12.9829 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2117 -13.6897 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6203 -14.3984 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.4417 -14.3958 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.8466 -13.6884 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8979 -9.3095 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
3 4 1 0
4 5 2 0
5 1 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
11 6 1 0
3 6 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 12 1 0
5 12 1 0
18 23 2 0
22 19 2 0
19 20 1 0
20 21 2 0
21 18 1 0
2 18 1 0
22 23 1 0
23 24 1 0
24 25 2 0
25 26 1 0
26 22 1 0
9 27 1 0
28 29 2 0
29 30 1 0
30 31 2 0
31 32 1 0
32 33 2 0
33 28 1 0
25 28 1 0
15 34 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 446.49Molecular Weight (Monoisotopic): 446.1543AlogP: 6.80#Rotatable Bonds: 4Polar Surface Area: 77.59Molecular Species: NEUTRALHBA: 3HBD: 3#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski): 1CX Acidic pKa: 9.64CX Basic pKa: 4.87CX LogP: 6.13CX LogD: 6.13Aromatic Rings: 6Heavy Atoms: 34QED Weighted: 0.28Np Likeness Score: -0.61
References 1. Selig R, Goettert M, Schattel V, Schollmeyer D, Albrecht W, Laufer S.. (2012) A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., 55 (19): [PMID:22951114 ] [10.1021/jm300852w ] 2. Juchum M, Günther M, Döring E, Sievers-Engler A, Lämmerhofer M, Laufer S.. (2017) Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping., 60 (11): [PMID:28482151 ] [10.1021/acs.jmedchem.7b00178 ] 3. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H.. (2022) Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer., 65 (2.0): [PMID:34323489 ] [10.1021/acs.jmedchem.1c00876 ]